Schizophrenia therapy developer Karuna among four biotechs to file for IPOs
Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans to go public Friday along with Bicycle, Peloton and Ideaya.
Backed by founding investor PureTech Health plc (LSE:PRTC), Karuna Therapeutics Inc. (Boston, Mass.) has raised $122 million across two venture rounds to